| Dysregulation of Myt1 expression acts as a potential peripheral biomarker for major depressive disorder and bipolar disorder. | Dysregulation of Myt1 expression acts as a potential peripheral biomarker for major depressive disorder and bipolar disorder.
Ghanbarirad M, Hashemi M, Saberi SM, Majd A. | 02/26/2022 |
| Novel MYT1 variants expose the complexity of oculo-auriculo-vertebral spectrum genetic mechanisms. | Novel MYT1 variants expose the complexity of oculo-auriculo-vertebral spectrum genetic mechanisms.
Zamariolli M, Burssed B, Moysés-Oliveira M, Colovati M, Bellucco FTDS, Dos Santos LC, Alvarez Perez AB, Bragagnolo S, Melaragno MI. | 01/8/2022 |
| MYT1 role in the microtia-craniofacial microsomia spectrum. | MYT1 role in the microtia-craniofacial microsomia spectrum.
Luquetti DV, Heike CL, Zarante I, Timms AE, Gustafson J, Pachajoa H, Porras-Hurtado GL, Ayala-Ramirez P, Duenas-Roque MM, Jimenez N, Ibanez LM, Hurtado-Villa P., Free PMC Article | 06/5/2021 |
| MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex. | MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex.
Chen K, Cai Y, Cheng C, Zhang J, Lv F, Xu G, Duan P, Wu Y, Wu Z. | 11/28/2020 |
| PICOT knock-down in Jurkat T cells resulted in a reduced histone H3 lysine 27 trimethylation (H3K27me3) at the PRC2 target gene, myelin transcription factor 1 (MYT1), suggesting that PICOT binding to EED alters PRC2-regulated transcriptional repression, and potentially contributes to the epigenetic regulation of chromatin silencing and remodeling. | PICOT binding to the polycomb group protein, EED, alters H3K27 methylation at the MYT1 PRC2 target gene.
Pandya P, Pasvolsky R, Babichev Y, Braiman A, Witte S, Altman A, Isakov N. | 11/2/2019 |
| Here we demonstrate that re-expression of Myt1 or Myt1l in glioblastoma (GBM) cell lines slows proliferation, that expression of both is lower in more aggressive sub-types of glioma, and that reduced expression correlates with poor prognosis in both GBM and low grade glioma, and our data suggest that Myt1 and Myt1l directly repress expression of YAP1, a protein which promotes proliferation and GBM growth. | Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression.
Melhuish TA, Kowalczyk I, Manukyan A, Zhang Y, Shah A, Abounader R, Wotton D., Free PMC Article | 06/1/2019 |
| wide analyses of the effects of Myt1 and Myt1l expression in a glioblastoma cell line suggest that the two proteins have largely similar effects on endogenous gene expression. Transcriptional repression is likely mediated by binding to DNA via the known consensus site, whereas this site is not associated with the transcriptional start sites of genes with higher expression in the presence of Myt1 or Myt1l. | Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors.
Manukyan A, Kowalczyk I, Melhuish TA, Lemiesz A, Wotton D. | 03/2/2019 |
| A novel missense variant affecting function, c.323C>T (p.(Ser108Leu)), was identified in MYT1, in a patient presenting with a severe form of OAVS. MYT1 overexpression downregulated all RA receptors genes in vitro. | A novel de novo mutation in MYT1, the unique OAVS gene identified so far.
Berenguer M, Tingaud-Sequeira A, Colovati M, Melaragno MI, Bragagnolo S, Perez ABA, Arveiler B, Lacombe D, Rooryck C., Free PMC Article | 12/9/2017 |
| although depletion of MYT1 alone did not affect long-term cell growth, it potentiated with DNA damage to inhibit cell growth in clonogenic survival and tumor xenograft models | The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery.
Chow JP, Poon RY. | 11/23/2013 |
| UVA-induced caspase-3 cleavage and DNA fragmentation were suppressed by the knockdown of human Myt1 in skin cancer cells. | c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer.
Choi HS, Bode AM, Shim JH, Lee SY, Dong Z., Free PMC Article | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.
Vega A, Salas A, Milne RL, Carracedo B, Ribas G, Ruibal A, de León AC, González-Hernández A, Benítez J, Carracedo A. | 11/5/2008 |
| present in brain in infancy and prenatally in infants with periventricular leukomalacia | Myelin transcription factor 1 (MyT1) immunoreactivity in infants with periventricular leukomalacia.
Hirayama A, Oka A, Ito M, Tanaka F, Okoshi Y, Takashima S. | 01/21/2010 |
| These results suggesta potential role for Myt1 in the regeneration of oligodendrocyte lineage cells in response to demyelination. | Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS.
Vana AC, Lucchinetti CF, Le TQ, Armstrong RC., Free PMC Article | 01/21/2010 |